Laurie Glimcher to step down as Dana-Farber president and CEO, Benjamin Levine Ebert named successor

Dana-Farber to pay $15M to U.S. government in research fraud settlement

Dana-Farber Cancer Institute has agreed to pay $15 million to the U.S. government in a settlement to resolve allegations that, between 2014 and 2024, Dana-Farber violated the False Claims Act by “using fraudulent images in grant applications and research articles to induce the NIH to pay millions of dollars to support research at Dana-Farber.”

Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research

The Dana-Farber/Harvard Cancer Center, a cancer research consortium comprised of five of Boston’s academic medical centers, including Dana-Farber Cancer Institute and Massachusetts General Hospital, has been awarded an NCI grant to continue its Specialized Program of Research Excellence in Breast Cancer.xxx:moreThe $12 million, five-year award represents a renewal of the DF/HCC

October 03, 2025

Vol.51 No.36

Clinical Roundup

Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows

A new class of drug results in cancer cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint known as the G1/S checkpoint, according to research gathered by the Oser Lab at Dana-Farber Cancer Institute.

September 12, 2025

Vol.51 No.33

Clinical Roundup

Peptide drug shows promise in treating glioblastoma, Virginia Tech researchers find

A lab-designed molecule developed and extensively studied by scientists with Virginia Tech’s Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer.

June 06, 2025

Vol.51 No.22

In Brief

Swim Across America grants $900,000 toward gene editing innovation

Swim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies. xxx:moreThe two-year grant

April 25, 2025

Vol.51 No.16

In Brief

Kimberly Stegmaier appointed chair of pediatric oncology at Dana-Farber

Kimberly Stegmaier was named chair of Pediatric Oncology at Dana-Farber Cancer Institute and associate chief of the Division of Hematology/Oncology at Boston Children’s Hospital. Her appointment is effective April 1.

February 21, 2025

Vol.51 No.07

Laurie Glimcher to step down as Dana-Farber president and CEO, Benjamin Levine Ebert named successor

YOU MAY BE INTERESTED IN

Dana-Farber to pay $15M to U.S. government in research fraud settlement

Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research

Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows

Peptide drug shows promise in treating glioblastoma, Virginia Tech researchers find

Swim Across America grants $900,000 toward gene editing innovation

Kimberly Stegmaier appointed chair of pediatric oncology at Dana-Farber

Renew today!

Subscriber content

Never miss an issue!

Login